PEG prodrugs of 6-mercaptopurine for parenteral administration using benzyl elimination of thiols

Oncology Research

Volumn 14, Issue 9, 2004, Pages 455-468

  Choe, Yun H ^a   Greenwald, Richard B ^a   Conover, Charles D ^a   Zhao, Hong ^a   Longley, Clifford B ^a   Guan, Shuiyun ^a   Zhao, Qiuxia ^a   Xia, Jing ^a  

^a Enzon Incorporated   (United States)

Author keywords

6 Mercaptopurine; Benzyl elimination; Parenteral administration; Poly(ethylene glycol); Prodrug

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; DRUG VEHICLE; MACROGOL; MERCAPTOPURINE; PRODRUG; THIOL DERIVATIVE;

ACUTE LYMPHOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMICAL MODIFICATION; CONJUGATION; CONTROLLED STUDY; DISSOCIATION CONSTANT; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG ELIMINATION; DRUG SOLUBILITY; DRUG SYNTHESIS; FEMALE; IN VITRO STUDY; MOUSE; NONHUMAN; PH MEASUREMENT; PRIORITY JOURNAL;

EID: 4644353135     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/0965040041791446     Document Type: Article

References (34)

1. Elion, G. B. The purine path to chemotherapy. Angew Chem. Int. Ed. Eng. 28:870-878; 1989.
2. Zimm, S.; Collins, J. M.; Riccardi, R.; O'Neill, D.; Narang, P. K.; Chabner, B.; Poplack, D. G. Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N. Engl. J. Med. 308:1005-1009; 1983.
3. Elion, G. B.; Hitchings, G. H.; Vanderwerff, H. Antagonists of nucleic acid derivatives VI. Purines. J. Biol. Chem. 192:505-518; 1951.
4. James, A.; Johnson, H., Jr.; Thomas, J.; Schaeffer, H. J. Synthesis of potential anticancer agents. XIII. Ribosides of 6-substituted purines. J. Am. Chem. Soc. 80:699-702; 1958.
5. Sloan, K. B.; Hashida, M.; Alexander, J.; Bodor, N.; Higuchi, T. Prodrugs of 6-thiopurines: Enhanced delivery through the skin. J. Pharm. Sci. 72:372-378; 1983.
6. Harada, N.; Hongu, M.; Tanaka, T.; Kashida, T.; Narasaki, N.; Ohohashi, M.; Oda, K.; Hashiyama, T.; Tsujihara, K. Water-soluble antitumor agents. I. Synthesis and biological activity of 6-S-aminoacyloxymethyl mercaptopurine derivatives. Chem. Pharm. Bull. 43:1793-1796; 1995.
7. Duncan, J. K.; Crawford, J. L.; Maddocks, D.; Jones, N.; Szawlowski, P. Rational design of novel immunosuppressive drugs: Analogues of azathioprine lacking the 6-mercaptopurine substituent retain or have enhanced immunosuppressive effects. J. Med. Chem. 39:2690-2695; 1996.
8. Greenwald, R. B.; Choe, Y. H.; McGuire, J.; Conover, C. D. Effective drug delivery by PEGylated drug conjugates. Adv. Drug Deliv. Rev. 55:217-250; 2003.
9. Wakselman, M. 1,4- and 1,6-Eliminations from hydroxy and amino-substituted benzyl systems: Chemical and biochemical applications. Nouv. J. Chem. 7:439-447; 1983.
10. Taylor, L. D.; Grasshoff, J. M.; Pluhar, M. Use of o- and p-hydroxybenzyl functions as blocking groups which are removable with base. J. Org. Chem. 43:1197-1200; 1978.
11. Greenwald, R. B.; Pendri, A.; Conover, C. D.; Zhao, H.; Choe, Y. H.; Martinez, A.; Shum, K.; Guan, S. Drug delivery systems employing 1,4- or 1,6-elimination: Poly (ethylene glycol) prodrugs of amine containing compounds. J. Med. Chem. 42:3657-3667; 1999.
12. Greenwald, R. B.; Choe, Y. H.; Conover, C. D.; Zhao, H.; Shum, K.; Wu, D.; Royzen, M. Drug delivery systems based on trimethyl lock lactonization: Poly (ethylene glycol) prodrugs of amine containing compounds. J. Med. Chem. 43:475-487; 2000.
13. Greenwald, R. B.; Gilbert, C. W.; Pendri, A.; Conover, C. D.; Xia, J.; Martinez, A. Drug delivery systems: Water soluble taxol 2′-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness. J. Med. Chem. 39:424-431; 1996.
14. 4-acyl poly (ethylene glycol) prodrugs of ara-c. I. Efficacy in solid tumors. J. Control Release 79:41-53; 2002.
15. Narang, P. K.; Yeager, R. L.; Chatterji, D. C. Quantitation of 6-mercaptopurine in biologic fluids using high-performance liquid chromatography: A selective and novel procedure. J. Chromatogr. 230:373-380; 1982.
16. 4-acyl poly (ethylene glycol) prodrugs of ara-C. II. Efficacy in ascites and solid tumors. J. Control Release 79:55-70; 2002.
17. Zuckermann, R. N.; Martin, E. J.; Spellmeyer, D. C.; Staruber, G. B.; Shoemaker, K. R.; Kerr, J. M.; Figliozzi, G. M.; Goff, D. A.; Siani, M. A.; Simon, R. J.; Banville, S. C.; Brown, E. G.; Wang, L.; Richter, L. S.; Moos, W. H. Discovery of nanomolar ligands for 7-transmembrane G-protein-coupled receptors from a diverse N-(substituted) glycine peptoid library. J. Med. Chem. 37: 2678-2685; 1994.
18. Greenwald, R. B.; Pendri, A.; Conover, C. D.; Lee, C.; Choe, Y. H.; Gilbert, C.; Martinez, A.; Xia, J.; Wu. D. Camptothecin-20-PEG ester transport forms: The effect of spacer groups on antitumor activity. Bioorg. Med. Chem. 6:551-562; 1998.
19. Greenwald, R. B.; Pendri, A.; Martinez, A.; Gilbert, C.; Bradley, R. PEG thiazolidine-2-thione, a novel reagent for facile protein modification: Conjugation of bovine hemoglobin. Bioconjugate Chem. 7:638-641; 1996.
20. Jones, J. W.; Robins, R. K. Potential purine antagonists. XXX. Purine betaines and related derivatives prepared by direct methylation of the simple purines. J. Am. Chem. Soc. 84:1914-1919; 1962.
21. Zorbach, W. W.; Tipson, R. S., eds. Synthetic procedures in nucleic acid chemistry, vol. 1. New York: John Wiley & Sons, Inc.; 1968.
22. Denny, W. A.; Wilson, W. R. The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies. J. Pharm. Pharmacol. 50:387-394; 1998.
23. Christenson, I. Alkaline hydrolysis of some carbamic acid esters. Acta Chem. Scand. 18:904-922; 1964.
24. Bender, M. L.; Homer, R. B. The mechanism of the alkaline hydrolysis of p-nitrophenyl N-methylcarbamate. J. Org. Chem. 30:3975-3978; 1965.
25. Friend, D. R.; Pangbum, S. Site-specific drug delivery. Med. Res. Rev. 7:53-106; 1987.
26. Burchenal, J. H.; Murphy, M. L.; Ellison, R. R.; Sykes, M. P.; Tan, T. C.; Leone, L. A.; Karnofsky, D. A.; Craver, L. F.; Dargeon, H. W.; Rhoads, C. P. Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases. Blood 11:965-1000; 1953.
27. Goldin, A.; Venditti, J. M.; Humphreys, S. R.; Dennis, D.; Mantel, N.; Greenhouse, S. W. Studies on the toxicity and antileukemic action of 6-mercaptopurine in mice. Ann. NY Acad. Sci. 60:251-266; 1954.
28. Skipper, H. E. Effects of 6-mercaptopurine on experimental tumors. Ann. NY Acad. Sci. 60:267-272; 1954.
29. Rose, W. C. Evaluation of Madison 109 lung carcinoma as a model for screening antitumor drugs. Cancer Treat. Rep. 65:299-312; 1981.
30. Zimm, S.; Ettinger, L. J.; Holcenberg, J. S.; Kamen, B. A.; Vietti, T. J.; Belasco, J.; Cogliano-Shutta, N.; Balis, F.; Lavi, L. E.; Collins, J. M.; Poplack, D. G. Phase I and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion. Cancer Res. 45:1869-1873; 1985.
31. Sahnoun, Z.; Serre-Debeauvais, F.; Lang J.; Faucon, G.; Gavend, M. Determination of 6-mercaptopurine and its metabolites in plasma or serum by high performance liquid chromatography. Biomed. Chromatogr. 4:144-147; 1990.
32. De Abreu, R. A.; Van Baal, J. M.; Schouten, T. J.; Schretlen, E. D. A. M.; De Bruyn, C. H. M. M. High-performance liquid chromatographic determination of plasma 6-mercaptopurine in clinically relevant concentrations. J. Chromatogr. 12:526-533; 1982.
33. Toki, B. E.; Cerveny, C. G.; Wahl, A. F.; Senter, P. D. Protease-mediated fragmentation of p-amidobenzylethers: A new strategy for the activation of anticancer prodrugs. J. Org. Chem. 67:1866-1872; 2002.
34. Maeda, H.; Seymour, L. W.; Miyamoto, Y. Conjugates of anticancer agents and polymers: Advantages of macromolecular therapeutics in vivo. Bioconjugate Chem. 3:351-362; 1992.